| Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. | |
| | |
MedLine Citation:
|
PMID: 17982632 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of this study was to evaluate the role of positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (18F-FDG) in the restaging of hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA). This study was performed on 33 lesions in 24 patients with HCC. 18F-FDG PET and computed tomography (CT) studies were performed in all patients before treatment. PET acquisition was started 50-60 min after injection of 18F-FDG (5-6 MBq/kg). Semi-quantitative analysis using Standardized Uptake Value (SUV) was measured for the evaluation of tumour 18F-FDG uptake. All patients underwent RFA treatment and were followed up at least 2 years with 18F-FDG PET, CT and clinical evaluation in the interval of every 3 months in the first year and every 6 months in the second year. 18F-FDG PET detected recurrence earlier than CT between 4-6 months in 2 patients and between 7-9 months in 6 patients whereas CT was positive in 4 patients. Overall detection rate of recurrence with 18F-FDG PET was 92% which was higher than that of CT (75%). Statistically significant difference in the SUV was observed between well and moderately differentiated HCC (p=0.033) and also between well and poorly differentiated HCC (p=0.037). The size of tumours showed a significant correlation with the time of recurrence (p<0.00033, r=0.8601, n=12). The results of this study indicate that 18F-FDG PET could detect recurrence earlier in patients with HCC treated with RFA, as compared with CT and could diagnose extrahepatic lesions. SUV showed a significant correlation with time of recurrence after RFA. 18F-FDG PET may be a dominant imaging modality as a follow-up procedure of HCC after RFA, in terms of early detection of recurrence. |
| | |
Authors:
|
Bishnuhari Paudyal; Noboru Oriuchi; Pramila Paudyal; Yoshito Tsushima; Yasuhiko Iida; Tetsuya Higuchi; Hirofumi Hanaoka; Mitsuyuki Miyakubo; Akie Takano; Tomohiro Ishikita; Keigo Endo |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Oncology reports Volume: 18 ISSN: 1021-335X ISO Abbreviation: Oncol. Rep. Publication Date: 2007 Dec |
Date Detail:
|
Created Date: 2007-11-05 Completed Date: 2008-01-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9422756 Medline TA: Oncol Rep Country: Greece |
Other Details:
|
Languages: eng Pagination: 1469-73 Citation Subset: IM |
Affiliation:
|
Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan. paudyal@med.gunma-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Carcinoma, Hepatocellular / pathology, radionuclide imaging*, therapy Catheter Ablation* Female Fluorodeoxyglucose F18 / diagnostic use* Humans Liver Neoplasms / pathology, radionuclide imaging*, therapy Male Middle Aged Positron-Emission Tomography Radiopharmaceuticals / diagnostic use Recurrence |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
Next Document: 17-beta-estradiol affects nuclear image properties in MCF-10F human breast epithelial cells with tum...